Edgewise Therapeutics (EWTX) Profit After Tax (2020 - 2026)
Edgewise Therapeutics (EWTX) reported Profit After Tax of -$49.9 million for Q1 2026, down 22.41% on a YoY basis from -$64.4 million in Q1 2025, and up 1.1% sequentially from -$50.5 million in Q4 2025.
Edgewise Therapeutics (EWTX) Profit After Tax (2020 - 2026) Analysis & Trends
Edgewise Therapeutics (EWTX) has 7 years of Profit After Tax data on file, last reported at -$49.9 million in Q1 2026.
- For the quarter ending Q1 2026, Profit After Tax fell 22.41% year-over-year to -$49.9 million; the trailing twelve-month figure through Mar 2026 stood at -$177.2 million (down 21.31% YoY), and the FY2025 full-year result was -$167.8 million, down 25.4% from the prior year.
- Profit After Tax climbed to -$49.9 million in Q1 2026, from -$50.5 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of -$14.7 million in Q1 2022 to a low of -$50.5 million in Q4 2025.
- A 5-year average of -$30.5 million and a median of -$28.7 million in 2023 frame the typical range for Profit After Tax.
- Across the five-year window, Profit After Tax sank 115.11% in 2022 and dropped 14.66% in 2025, its largest moves.
- Tracing EWTX's Profit After Tax over 5 years: stood at -$20.3 million in 2022, then slumped by 41.63% to -$28.7 million in 2023, then tumbled by 38.25% to -$39.7 million in 2024, then decreased by 27.32% to -$50.5 million in 2025, then climbed by 1.1% to -$49.9 million in 2026.
- Business Quant data shows EWTX's Profit After Tax at -$49.9 million in Q1 2026, -$50.5 million in Q4 2025, and -$40.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -36.84 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -65.60 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Edgewise Therapeutics | 4.37 Bn | 4.37 Bn | - | -49.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -49.94 Mn |
| Dec 31, 2025 | -50.50 Mn |
| Sep 30, 2025 | -40.67 Mn |
| Jun 30, 2025 | -36.12 Mn |
| Mar 31, 2025 | -40.80 Mn |
| Dec 31, 2024 | -39.66 Mn |
| Sep 30, 2024 | -34.13 Mn |
| Jun 30, 2024 | -31.50 Mn |
| Mar 31, 2024 | -28.53 Mn |
| Dec 31, 2023 | -28.69 Mn |
| Sep 30, 2023 | -25.71 Mn |
| Jun 30, 2023 | -21.47 Mn |
| Mar 31, 2023 | -22.84 Mn |
| Dec 31, 2022 | -20.26 Mn |
| Sep 30, 2022 | -17.34 Mn |
| Jun 30, 2022 | -16.07 Mn |
| Mar 31, 2022 | -14.66 Mn |
| Dec 31, 2021 | -12.67 Mn |
| Sep 30, 2021 | -12.94 Mn |
| Jun 30, 2021 | -10.35 Mn |